The potential action of SSRIs in the treatment of skin diseases including atopic dermatitis and slow-healing wounds

Pharmacol Rep. 2022 Oct;74(5):947-955. doi: 10.1007/s43440-022-00423-7. Epub 2022 Oct 7.

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are used to treat affective and anxiety disorders. Antidepressants have also been shown to have antimicrobial and immunomodulatory effects, which may affect the microbiota-intestinal-brain axis. Studies show that SSRIs have antimicrobial activity both in vivo and in vitro and influence bacteria by inhibiting biofilm, affecting efflux pumps, among others. A huge challenge today is the prevention and treatment of skin diseases, including atopic dermatitis (AD) and slow-healing wounds. Skin diseases including AD and non-healing wounds are serious medical problem. People suffering from these conditions feel constant discomfort, which also affects their psychological state. Research on new treatments for AD and slow-healing wounds is essential because current medications are not fully effective and have many side effects. Exploring new drug groups for AD and slow-healing wounds will allow for the creation of an alternative treatment for these diseases. SSRIs represent a hope for the treatment of skin diseases due to their immunomodulatory and antimicrobial properties.

Keywords: Antidepressants; Atopic dermatitis; Microbiota; Selective serotonin reuptake inhibitors; Slow-healing wounds.

Publication types

  • Review

MeSH terms

  • Antidepressive Agents
  • Anxiety
  • Dermatitis, Atopic* / drug therapy
  • Humans
  • Serotonin Uptake Inhibitors* / pharmacology
  • Serotonin Uptake Inhibitors* / therapeutic use

Substances

  • Serotonin Uptake Inhibitors
  • Antidepressive Agents